Supriya Lifescience Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

SUPRIYA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.1%Reaction day

₹731.00

prior close

₹750.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.3%-1.5% vs market

Pharmaceuticals peers, median of 147sector-0.3%-0.8% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

-1.1

15m

-2.7

30m

-2.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.1+0.3-1.5-0.3-0.8

Next day

+2.8+0.7+2.1+0.2+2.6

-0.4+1.0-1.4-0.2-0.2

-2.2+1.1-3.3-0.3-2.0

-2.3+0.8-3.1-0.6-1.7

-4.2+1.3-5.5-0.6-3.6

-5.6+1.7-7.4-0.4-5.2

15d

-7.5+1.5-8.9-1.0-6.4

-3.0+4.0-7.0+0.0-3.0

-8.1+1.8-9.9+0.0-8.2

-10.0-1.0-9.0-3.4-6.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Supriya Lifescience Limited reported strong audited results for the year ended March 31, 2025. Revenue from operations grew 22.1% year-on-year to Rs. 6,964.85 million, while profit after tax surged 57.8% to Rs. 1,879.58 million. EPS stood at Rs. 23.35 versus Rs. 14.80 in the previous year. The Board recommended a final dividend of Re. 1.00 per share (50% on face value of Rs. 2), subject to shareholder approval. Statutory auditor Kakaria & Associates LLP issued an unmodified opinion on the results. The company also appointed M/s. DSM & Associates as Secretarial Auditors for a five-year term starting FY 2025-26.

Likely market impact

This is a strong set of results for shareholders — both top-line growth and bottom-line expansion are well above industry norms, and the company remains debt-free with a healthy equity base of nearly Rs. 10,000 million. The dividend announcement rewards investors, and the clean audit opinion signals good financial governance.